Market Overview

Investigation Report on Chinese Atorvastatin Market, 2018-2022: The Global Sales of Lipitor had Exceeded USD 150 Billion, Creating a Miracle in Global Drug Sales

Share:

Investigation Report on Chinese Atorvastatin Market, 2018-2022: The Global Sales of Lipitor had Exceeded USD 150 Billion, Creating a Miracle in Global Drug Sales

PR Newswire

DUBLIN, Aug. 15, 2018 /PRNewswire/ --

The "Investigation Report on Chinese Atorvastatin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The number of patients with hyperlipidemia is increasing in China with the lifestyle change resulting from the economic development and the rise of residents' income. It is estimated that there are over 100 million patients with hyperlipidemia and 160 million patients with dyslipidemia in China. And the figures are increasing every year.

Atorvastatin is a common drug that lowers blood cholesterol levels. It was developed by Pfizer in the trade name of Lipitor. It has been proved that Atorvastatin is safe and can decrease major cardiovascular events for patients with coronary heart disease, ischemic stroke, diabetes and high-risk patients with cardiovascular diseases such as hypertension. By the end of 2017, the global sales of Lipitor had exceeded USD 150 billion, creating a miracle in global drug sales.

According to the researcher, Atorvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 200 million in 2005 to more than CNY 2.21 billion in 2017. There is a high demand for Atorvastatin in China. In addition to Pfizer's brand-name drug Lipitor, generic drugs of Beijing Jialin Pharmaceutical Co., Ltd., China Meheco Topfond Pharma Co., Ltd., Zhejiang Neo-Dankong Pharmaceutical Co., Ltd., Guangdong Baike Pharmaceutical Co., Ltd., etc. are also sold on the market. Pfizer captured the largest market share by sales value. Its market share exceeded 70% with a sales value over CNY 1.6 billion in 2017.

It is estimated that the number of patients with hyperlipidemia will continue to grow in China in the next few years, which will lead to a rising demand for Atorvastatin.

Topics Covered:

  • Development environment of Atorvastatin in China
  • Sales of Atorvastatin in China
  • Prices of Atorvastatin in China
  • Major Atorvastatin manufacturers in China
  • Market share of Atorvastatin by dosage form in China
  • Prospect of Chinese Atorvastatin Market, 2018-2022

Key Topics Covered:

1 Relevant Concepts of Atorvastatin
1.1 Indications for Atorvastatin
1.2 Development History of Atorvastatin in China
1.3 Patents and Government Approval on Atorvastatin in China

2 Sales of Atorvastatin in China, 2013-2017
2.1 Sales Value of Atorvastatin
2.1.1 Overall Sales Value
2.1.2 Sales Value in Parts of China
2.2 Sales Volume of Atorvastatin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Atorvastatin by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules

3 Analysis On Major Atorvastatin Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Atorvastatin Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer's Atorvastatin in China
3.3 Beijing Jialin Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Beijing Jialin Pharmaceutical Co., Ltd.'s Atorvastatin in China
3.4 China Meheco Topfond Pharma Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of China Meheco Topfond Pharma Co., Ltd.'s Atorvastatin in China
3.5 Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.'s Atorvastatin in China
3.6 Guangdong Baike Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Guangdong Baike Pharmaceutical Co., Ltd.'s Atorvastatin in China

4 Prices of Different Manufacturers' Atorvastatin in China, 2017-2018
4.1 Pfizer (Trade Name: Lipitor)
4.2 Beijing Jialin Pharmaceutical Co., Ltd. (Trade Name: Ale)
4.3 China Meheco Topfond Pharma Co., Ltd. (Trade Name: Youjia)
4.4 Zhejiang Neo-Dankong Pharmaceutical Co., Ltd. (Trade Name: Youliping)
4.5 Guangdong Baike Pharmaceutical Co., Ltd. (Trade Name: Jingshu)

5 Prospect of Chinese Atorvastatin Market, 2018-2022
5.1 Factors Influencing Development
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/research/xzsf7w/investigation?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/investigation-report-on-chinese-atorvastatin-market-2018-2022-the-global-sales-of-lipitor-had-exceeded-usd-150-billion-creating-a-miracle-in-global-drug-sales-300697621.html

SOURCE Research and Markets

View Comments and Join the Discussion!